about
The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemiaIdarubicin compared to other anthracyclines for treatment of newly diagnosed acute myeloid leukaemiaA single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trialAnti-CHMP5 single chain variable fragment antibody retrovirus infection induces programmed cell death of AML leukemic cells in vitroSouthwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemiaExpression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy.Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignanciesEpigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia.Angiogenesis in acute myeloid leukemia and opportunities for novel therapies.Identification of circulating microRNAs as biomarkers in diagnosis of hematologic cancers: a meta-analysis.Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia.Perspectives of proteomics in acute myeloid leukemia.Clinical significance of in vivo cytarabine-induced gene expression signature in AML.Potential role of sorafenib in the treatment of acute myeloid leukemia.Subcellular localization of DJ-1 in human HL-60 leukemia cells in response to diallyl disulfide treatment.Treatment of acute promyelocytic leukemia during pregnancy.All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia.Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands.Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults.The role of decitabine for the treatment of acute myeloid leukemia.GSTT1 and GSTM1 polymorphisms predict treatment outcome for acute myeloid leukemia: a systematic review and meta-analysis.Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.A retrospective study of leukemia epidemiology in Northern Tunisia.Mimic of manganese superoxide dismutase induces apoptosis in human acute myeloid leukemia cells.Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line.Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response.Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents.Angiogenesis Status in Patients with Acute Myeloid Leukemia: From Diagnosis to Post-hematopoietic Stem Cell TransplantationMitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin.Outcome and prognostic factors of patients with acute leukemia admitted to the intensive care unit for septic shock.Expert insights into the contemporary management of older adults with acute myeloid leukemia.Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia.The Angiogenic Chemokines Expression Profile of Myeloid Cell Lines Co-Cultured with Bone Marrow-Derived Mesenchymal Stem Cells.Efficacy of intracellular immune checkpoint-silenced DC vaccine.Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemia.Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia.Cardiac Tamponade as the Initial Presentation of Acute Myeloid Leukemia: A Case Report with Review of the Literature.Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations
P2860
Q24187297-BB5AF9C9-0141-496F-A2A2-1A1A8E05A979Q24200407-F5CF2CB6-D0D6-4B57-BA92-3744A2065505Q33350688-DE4A08CA-8D5B-431B-82CC-528F358D6EB1Q33567527-A135387A-3990-4899-8EFF-7433DED46FFFQ33598706-C858EA18-BB3B-4F0C-AD05-601770E7566CQ33636086-937403F6-D03F-4274-B32E-77B16205F112Q34367804-6448406B-21B8-4204-BA89-5C38694BB017Q34643306-281240FD-46D4-4EA3-81F8-D060403E642BQ35196950-830F08F3-976B-4BD9-9C3E-6499196B7175Q35211371-60C6B716-7878-4B30-A7A7-231C7046C49AQ36630868-A1265D7E-70C5-4826-96A5-25281309F1B1Q36668271-BF004CAF-35EA-4EFE-9E52-05FC2B5C6F07Q36693136-9D3DDB5D-160D-4061-8C5D-83D2A76DD5BDQ37340403-5BFCD339-542C-4BCA-BD2E-B5D0F162AC8BQ37403602-5ADB87DD-FCE9-4907-8037-F8D48271B83CQ37498872-B71A870D-8CA8-48D8-967C-316627EC76A3Q37538521-FFE2A207-4E24-423E-864D-50CD7F150CA2Q37885284-11CE8E52-31A1-4FCF-9403-1BFB2F56D2BFQ37968584-6D060FC1-ACAC-4AA3-930F-E3EF7CEF1285Q38056891-917A88C2-7AA0-4DA9-9C3F-12D77F70A44EQ38226249-1933FEC8-FC5B-4EBC-B1D0-3FB1855006A3Q38522618-056E45C8-3E58-42B4-A5FC-288EE9C10BFEQ38614756-E1D03EB7-25A8-42AA-BF61-B11605793185Q39045544-A35FD1BB-4B6C-4114-9AC8-5929990BE6AEQ39121433-685C917E-E1BB-4A23-80EA-DD94E5621955Q39210200-41E7B6B4-C788-4A4F-8511-D9525BE50904Q39590174-5F45A9CE-3B27-46D5-9ACD-F903A9F1B2D2Q40385613-B1101D6E-0AA6-42AA-ACD6-8382FC86DD15Q41313323-0A797967-52DB-4122-8151-AF43A67E7064Q43254037-5DE4F25B-290F-4C42-8A7B-B18926300BD2Q43445240-5E45621E-9873-4C5A-8CA6-A685060B97C7Q44898238-6353965C-D84D-43F2-AFFA-FB8F346A0214Q46952293-79BD816A-E52A-4D78-A399-65FB6B87756CQ50116329-8F158E7F-C856-4A1B-B4A0-4F3F7C88F0EBQ50130525-060AF12B-7F36-4EB6-AC72-A9C6D232B17CQ53164864-2F69B99B-901A-455C-96E7-9B416CCB167EQ54527759-9CBF7EE0-747A-400C-B67E-06521BD26AB0Q55046616-01DB0719-EDEC-41BC-81A1-F26886C8FD78Q57815598-8D7A783E-CAD1-43FF-9508-1FE1869AFFC7
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Adult acute myeloid leukemia.
@ast
Adult acute myeloid leukemia.
@en
type
label
Adult acute myeloid leukemia.
@ast
Adult acute myeloid leukemia.
@en
prefLabel
Adult acute myeloid leukemia.
@ast
Adult acute myeloid leukemia.
@en
P356
P1476
Adult acute myeloid leukemia.
@en
P2093
Elias J Jabbour
Elihu Estey
P304
P356
10.4065/81.2.247
P407
P577
2006-02-01T00:00:00Z